Literature DB >> 21521749

Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary.

M Victoria Recouvreux1, M Clara Guida, Daniel B Rifkin, Damasia Becu-Villalobos, Graciela Díaz-Torga.   

Abstract

Dopamine, acting through the dopamine type 2 receptor (Drd2), is the main inhibitor of pituitary prolactin (PRL) secretion and lactotroph proliferation. TGF-β1 is involved, at least in part, in mediating these actions. It was described that TGF-β1 synthesis in rat pituitary lactotrophs is up-regulated by dopamine and down-regulated by estradiol. TGF-β1 is secreted as a large latent complex. The local regulation of cytokine activation in the pituitary has not yet been explored. In this work, we studied pituitary active and total TGF-β1 content, as well as TGF-β1 mRNA, and the in vivo role of dopamine and estradiol on pituitary TGF-β1 levels. Adult female mice (wild type), and female mice with a null mutation in the Drd2 (Drd2(-/-)), were used. The loss of dopaminergic tone induced a decrease in TGF-β1 mRNA expression, in active and total cytokine content, and in TGF-β type II receptor expression. Dopamine regulation of pituitary TGF-β1 activation process was inferred by the inhibition of active cytokine by in vivo sulpiride treatment. Interestingly, in the absence of dopaminergic tone, estradiol induced a strong increase in active TGF-β1. PRL secretion correlated with active, but not total cytokine. TGF-β1 inhibitory action on lactotroph proliferation and PRL secretion was decreased in Drd2(-/-) pituitary cells, in correlation with decreased TGF-β type II receptor. The study of the TGF-β1 activation process and its regulation is essential to understand the cytokine activity. As an intermediary of dopamine inhibition of lactotroph function, TGF-β1 and local activators may be important targets in the treatment of dopamine agonist-resistant prolactinomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21521749      PMCID: PMC3115611          DOI: 10.1210/en.2010-1464

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  29 in total

1.  Dopamine and transforming growth factor-beta1: an odd couple in growth inhibition of the lactotrophs.

Authors:  Nira Ben-Jonathan
Journal:  Endocrinology       Date:  2005-10       Impact factor: 4.736

2.  Analysis of homogeneous populations of anterior pituitary folliculostellate cells by laser capture microdissection and reverse transcription-polymerase chain reaction.

Authors:  L Jin; I Tsumanuma; K H Ruebel; J M Bayliss; R V Lloyd
Journal:  Endocrinology       Date:  2001-05       Impact factor: 4.736

Review 3.  Dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma.

Authors:  Carolina Cristina; Isabel García-Tornadú; Graciela Díaz-Torga; Marcelo Rubinstein; Malcolm J Low; Damasia Becú-Villalobos
Journal:  Front Horm Res       Date:  2006       Impact factor: 2.606

4.  Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice.

Authors:  S L Asa; M A Kelly; D K Grandy; M J Low
Journal:  Endocrinology       Date:  1999-11       Impact factor: 4.736

Review 5.  Regulation of pituitary hormones and cell proliferation by components of the extracellular matrix.

Authors:  M Paez-Pereda; F Kuchenbauer; E Arzt; G K Stalla
Journal:  Braz J Med Biol Res       Date:  2005-09-06       Impact factor: 2.590

6.  Bromocriptine restores angiotensin II response in pituitary hyperplasia.

Authors:  A González Iglesias; G Díaz-Torga; G Piroli; R Achával-Zaia; A F De Nicola; C Libertun; D Becu-Villalobos
Journal:  Mol Cell Endocrinol       Date:  2000-07-25       Impact factor: 4.102

7.  Transforming growth factor-beta3 stimulates lactotrope cell growth by increasing basic fibroblast growth factor from folliculo-stellate cells.

Authors:  S Hentges; N Boyadjieva; D K Sarkar
Journal:  Endocrinology       Date:  2000-03       Impact factor: 4.736

8.  Changes in thrombospondin-1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumors.

Authors:  Abby J Sarkar; Kirti Chaturvedi; Cui Ping Chen; Dipak K Sarkar
Journal:  J Endocrinol       Date:  2007-02       Impact factor: 4.286

9.  Ethanol alters production and secretion of estrogen-regulated growth factors that control prolactin-secreting tumors in the pituitary.

Authors:  Dipak K Sarkar; Nadka I Boyadjieva
Journal:  Alcohol Clin Exp Res       Date:  2007-12       Impact factor: 3.455

10.  Perturbation of transforming growth factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors.

Authors:  Keiji Yoshinaga; Hiroto Obata; Vladimir Jurukovski; Roberta Mazzieri; Yan Chen; Lior Zilberberg; David Huso; Jonathan Melamed; Petra Prijatelj; Vesna Todorovic; Branka Dabovic; Daniel B Rifkin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-20       Impact factor: 11.205

View more
  11 in total

1.  Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1).

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Damasia Becu-Villalobos; Graciela Díaz-Torga
Journal:  Endocrinology       Date:  2012-06-14       Impact factor: 4.736

2.  Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomas.

Authors:  M Victoria Recouvreux; Lara Lapyckyj; M Andrea Camilletti; M Clara Guida; Ana Ornstein; Daniel B Rifkin; Damasia Becu-Villalobos; Graciela Díaz-Torga
Journal:  Endocrinology       Date:  2013-09-05       Impact factor: 4.736

3.  Dynamic mechanical compression of devitalized articular cartilage does not activate latent TGF-β.

Authors:  Michael B Albro; Robert J Nims; Alexander D Cigan; Kevin J Yeroushalmi; Jay J Shim; Clark T Hung; Gerard A Ateshian
Journal:  J Biomech       Date:  2013-03-27       Impact factor: 2.712

Review 4.  The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Graciela Díaz-Torga
Journal:  J Endocrinol       Date:  2015-12-23       Impact factor: 4.286

5.  Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo.

Authors:  Chao Tang; Junhao Zhu; Feng Yuan; Jin Yang; Xiangming Cai; Chiyuan Ma
Journal:  Mol Neurobiol       Date:  2021-08-31       Impact factor: 5.590

6.  The expression of TGF-β1, Smad3, phospho-Smad3 and Smad7 is correlated with the development and invasion of nonfunctioning pituitary adenomas.

Authors:  Li Zhenye; Li Chuzhong; Wu Youtu; Lan Xiaolei; Cao Lei; Hong Lichuan; Wang Hongyun; Wu Yonggang; Wang Fei; Zhang Yazhuo
Journal:  J Transl Med       Date:  2014-03-18       Impact factor: 5.531

7.  Prolactin induces apoptosis of lactotropes in female rodents.

Authors:  Jimena Ferraris; Sandra Zárate; Gabriela Jaita; Florence Boutillon; Marie Bernadet; Julien Auffret; Adriana Seilicovich; Nadine Binart; Vincent Goffin; Daniel Pisera
Journal:  PLoS One       Date:  2014-05-23       Impact factor: 3.240

8.  Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats.

Authors:  Ping Li; Songbai Gui; Lei Cao; Hua Gao; Jiwei Bai; Chuzhong Li; Yazhuo Zhang
Journal:  Onco Targets Ther       Date:  2016-04-06       Impact factor: 4.147

9.  Meta-type analysis of dopaminergic effects on gene expression in the neuroendocrine brain of female goldfish.

Authors:  Jason T Popesku; Christopher J Martyniuk; Vance L Trudeau
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-02       Impact factor: 5.555

10.  Genetic variants in transforming growth factor-β gene (TGFB1) affect susceptibility to schizophrenia.

Authors:  Dorota Frydecka; Blazej Misiak; Jan Aleksander Beszlej; Lidia Karabon; Edyta Pawlak-Adamska; Anna Tomkiewicz; Anna Partyka; Anna Jonkisz; Andrzej Kiejna
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.